- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05110716
Effects of Choice Bundling on Valuation of Delayed Gains and Losses in Cigarette Smokers
26. oktober 2021 opdateret af: Warren K. Bickel, Virginia Polytechnic Institute and State University
The present study will investigate the effects of choice bundling, in which a single choice produces a series of repeating consequences, on valuation of delayed monetary gains and losses in an online panel of cigarette smokers.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Choice bundling, in which a single choice produces a series of repeating consequences, has been shown to increase valuation of delayed monetary and non-monetary gains.
Interventions derived from this manipulation may be an effective method for mitigating the elevated delay discounting rates observed in cigarette smokers.
No prior work, however, has investigated whether effects of choice bundling generalize to reward losses.
In the present study, an online panel of cigarette smokers, recruited using Ipsos, will complete assessments for either monetary gains or losses (randomly assigned).
In Step 1, participants will complete a delay-discounting task to establish Effective Delay 50 (ED50), or the delay required for a monetary outcome to lose half of its value.
In Step 2, participants will complete three conditions of an adjusting-amount task, choosing between a smaller, sooner (SS) adjusting amount and a larger, later (LL) fixed amount.
The bundle size (i.e., number of consequences) will be manipulated across conditions, where a single choice will produce either 1 (control), 3, or 9 consequences over time (ascending/descending order counterbalanced).
The delay to the first LL amount in each condition, as well as the intervals between all additional SS and LL amounts (where applicable), will be set to individual participants' ED50 values from Step 1 to control for differences in discounting of gains and losses.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
308
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Virginia
-
Roanoke, Virginia, Forenede Stater, 24016
- Fralin Biomedical Research Institute at VTC
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
21 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- currently smoke at least 10 cigarettes per day
- have smoked at least 100 cigarettes (lifetime), and
- are 21 years of age or older.
Exclusion Criteria:
- Inaccurate identification of usual brand cigarette's as menthol or non-menthol
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Gains, Ascending Bundle-Size Order
Participants will complete the choice bundling adjusting-amount task for monetary gains in an ascending order of bundle size.
|
In this condition, each choice in the adjusting-amount task produces only a single consequence (e.g., lose $900 in 1 year).
In this condition, each choice in the adjusting-amount task produce a series of three consequences over time.
o hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series.
(e.g., lose $300 in 1 year, lose $300 in 2 years, lose $300 in 3 years).
In this condition, each choice in the adjusting-amount task produce a series of nine consequences over time.
To hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series.
(e.g., lose $100 in 1 year, lose $100 in 2 years, lose $100 in 3 years...lose $100 in 9 years).
|
Eksperimentel: Gains, Descending Bundle-Size Order
Participants will complete the choice bundling adjusting-amount task for monetary gains in a descending order of bundle size.
|
In this condition, each choice in the adjusting-amount task produces only a single consequence (e.g., lose $900 in 1 year).
In this condition, each choice in the adjusting-amount task produce a series of three consequences over time.
o hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series.
(e.g., lose $300 in 1 year, lose $300 in 2 years, lose $300 in 3 years).
In this condition, each choice in the adjusting-amount task produce a series of nine consequences over time.
To hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series.
(e.g., lose $100 in 1 year, lose $100 in 2 years, lose $100 in 3 years...lose $100 in 9 years).
|
Eksperimentel: Losses, Ascending Bundle-Size Order
Participants will complete the choice bundling adjusting-amount task for monetary losses in an ascending order of bundle size.
|
In this condition, each choice in the adjusting-amount task produces only a single consequence (e.g., lose $900 in 1 year).
In this condition, each choice in the adjusting-amount task produce a series of three consequences over time.
o hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series.
(e.g., lose $300 in 1 year, lose $300 in 2 years, lose $300 in 3 years).
In this condition, each choice in the adjusting-amount task produce a series of nine consequences over time.
To hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series.
(e.g., lose $100 in 1 year, lose $100 in 2 years, lose $100 in 3 years...lose $100 in 9 years).
|
Eksperimentel: Losses, Descending Bundle-Size Order
Participants will complete the choice bundling adjusting-amount task for monetary losses in an ascending order of bundle size.
|
In this condition, each choice in the adjusting-amount task produces only a single consequence (e.g., lose $900 in 1 year).
In this condition, each choice in the adjusting-amount task produce a series of three consequences over time.
o hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series.
(e.g., lose $300 in 1 year, lose $300 in 2 years, lose $300 in 3 years).
In this condition, each choice in the adjusting-amount task produce a series of nine consequences over time.
To hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series.
(e.g., lose $100 in 1 year, lose $100 in 2 years, lose $100 in 3 years...lose $100 in 9 years).
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Indifference points
Tidsramme: 1 day (same session)
|
Participants complete three conditions of the adjusting-amount task (one at each bundle size), in which they choose between a larger, delayed amount ($900) and a smaller, immediate amount.
Across trials, the smaller amount titrates until reaching an indifference point.
This indifference point provides an index of the value of the larger option.
For example, an indifference point of $300 indicates the larger, delayed amount as been discounted by two thirds.
Higher values reflect less delay discounting.
|
1 day (same session)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Warren K Bickel, PhD, Virginia Polytechnic Institute and State University
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
26. juli 2021
Primær færdiggørelse (Faktiske)
12. august 2021
Studieafslutning (Faktiske)
12. august 2021
Datoer for studieregistrering
Først indsendt
11. oktober 2021
Først indsendt, der opfyldte QC-kriterier
26. oktober 2021
Først opslået (Faktiske)
8. november 2021
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
8. november 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
26. oktober 2021
Sidst verificeret
1. oktober 2021
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- 20-827
- 5P01CA217806 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
JA
IPD-planbeskrivelse
De-identified participant data will be made available from the Open Science Framework (OSF) database.
The url providing access to data will be provided in study publications.
IPD-delingstidsramme
Data will become available immediately upon publication of the manuscript and will remain available for 5 years.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Cigaretrygning
-
Assistance Publique - Hôpitaux de ParisUkendtRygestop | Rygning, cigaret | Elektronisk cigaretFrankrig
-
University of VermontNational Institute on Drug Abuse (NIDA)AfsluttetBrug af elektronisk cigaret | Vaping | Brug af e-cigaretForenede Stater
-
University of Southern CaliforniaAfsluttetBrug af elektronisk cigaret | Cigaretrygning | Brug af cigaret, elektronisk | VapingForenede Stater
-
University of Southern CaliforniaAfsluttetBrug af elektronisk cigaret | Cigaretrygning | Brug af cigaret, elektronisk | VapingForenede Stater
-
Andrew StrasserNational Cancer Institute (NCI); University of Pennsylvania; Food and Drug...Rekruttering
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)Afsluttet
-
Jeil Pharmaceutical Co., Ltd.AfsluttetRygning, cigaretKorea, Republikken
-
Brown UniversityNational Institute on Drug Abuse (NIDA)RekrutteringBrug af elektronisk cigaret | Rygning, cigaretForenede Stater
-
University of Southern CaliforniaAfsluttetBrug af elektronisk cigaret | Cigaretrygning | Brug af cigaret, elektronisk | VapingForenede Stater
-
Juul Labs, Inc.AfsluttetBrug af tobak | Tobaksrygning | Brug af elektronisk cigaret | Brug af cigaret, elektroniskForenede Stater
Kliniske forsøg med Bundle-size 1
-
The University of Texas Health Science Center,...National Heart, Lung, and Blood Institute (NHLBI); United States Department... og andre samarbejdspartnereAfsluttetTraumaForenede Stater, Canada
-
Orasis Pharmaceuticals Ltd.Afsluttet
-
University of ThessalyAfsluttet
-
Queen Margaret UniversityNHS LothianAfsluttet
-
Chulalongkorn UniversityAfsluttetAllergisk rhinitisThailand
-
University of Sao Paulo General HospitalAfsluttetOveraktiv blæresyndromBrasilien
-
University of Sao Paulo General HospitalAfsluttet
-
Montreal Heart InstituteInstitut de Recherches Cliniques de Montreal; Royal Victoria Hospital,... og andre samarbejdspartnereAfsluttetHypertriglyceridæmiCanada
-
Yonsei UniversityAfsluttetOvervægtige patienter, én lungeventilationKorea, Republikken
-
Janssen Research & Development, LLCAfsluttetRecidiverende eller refraktært Hodgkin-lymfomFrankrig, Tyskland